

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: <u>www.ajoonibiotech.com</u> E-mail: <u>ajooni.biotech@gmail.com</u> / <u>info@ajoonibiotech.com</u>

CIN: L85190PB2010PLC040162

November 09, 2023

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Dear Sir / Madam,

<u>Subject:</u> Outcome of the Board Meeting held on Thursday, 09th November 2023, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Thursday, 09th November 2023 at 11.30 a.m concluded at 12.00 noon. Following transactions were considered and approved:

- 1. The un-audited Financial Results for the quarter and half year ended September 30, 2023.
- 2. Limited Review Report for the quarter and half year ended September 30, 2023.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You, Yours Truly, For Ajooni Biotech Limited

Jasjot Singh Managing Director DIN: 01937631



Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: <u>www.ajoonibiotech.com</u> E-mail: <u>ajooni.biotech@gmail.com</u> / <u>info@ajoonibiotech.com</u>

CIN: L85190PB2010PLC040162

November 09, 2023

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter and half year ended September 30, 2023.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Thursday, November 09, 2023 at the Registered Office of the company have considered and approved the Un-audited Financial Results quarter and half year ended September 30, 2023. In this regards, we are enclosing herewith:

- 1. Un-audited Financial Results for the quarter and half year ended September 30, 2023 as recommended by the Audit Committee.
- 2. Limited Review Report for the quarter and half year ended September 30, 2023.

You are requested to kindly take the same on record.

Thanking You, Yours Truly, For Ajooni Biotech Limited

Jasjot Singh Managing Director DIN: 01937631

STATEMENT OF STANDALIONE FINANCIAL RESULTS FOR THE QUANTER & DUED GOTT I STATT MERK ACC TANDALIONE FINANCIAL RESULTS FOR THE QUANTER & DUED GOTT I STATT MERK Very Ended Funda PARTIFICULA NES xonsassi Distribution xonsassi xonsassi xonsassi Distribution xonsassi xonsassi Xonsassi xonsassi Xonsassi xonsassi Colspan="2" xonsassi Xonsassi xonsassi Xonsassi xonsassi Xonsassi xo	STATENENT OF STANDALOME INANCIAL RESULTS FOR THE QUARTER ENDED 2017 Refer Revol Refer Automical Automi	STATEMENT OF STAND. PARTICULARS		0114 · FOO 1301 DE0 101 FC040 105	701040	and the second se		
PARTECLIARS Non-Title Non-Title Non-Title Non-Title Non-Title Non-Title Non-Title Non-Title Non-Title Non-State	Invention Towards Source freed (state) Source freed (state) Source freed (state) Intermedie 1.01232 1.00331 1.00331 1.00331 Source freed (state) J.00331 Intermedie 1.01731 1.00311 1.01031 1.00314 J.00331 J.00331 Intermente 1.01731 1.00314 4.004.08 2.0133 J.00331 Intermente 1.01731 1.00314 4.004.08 2.0133 J.00331 Intermente 1.01731 1.00314 1.00334 4.004.08 J.00331 J.00331 Intermente 1.01014 1.01034 4.004.08 2.0133 J.00331 Intermente 1.01014 1.01034 4.004.08 2.0133 J.00331 Intermente 1.01016 1.01033 1.0133 3.0133 J.0133 J.0133 J.01331 Intermente 1.01016 1.01033 1.01033 J.0133 J.0133 J.0133 J.01331 J.01331 J.01331 J.01331 J.01331 J.01331 J.	PARTICULARS	ALONE FINANCIAL RESUL	TS FOR THE QU	ARTER ENDE	D 30TH SEPT	EMBER 2023 (h	ı Lakhs)
Subset	Offention (matrix) Software (matrix)							Year Ended (Audited)
Income 0008-0023 0008-0033 0008-003 0008-003-003 <t< th=""><th>Internet State State</th><th></th><th>30.09.2023</th><th>30.06.2023</th><th>30.09.2022</th><th>Period Ended (UnAudited)</th><th>Period Ended (UnAudited)</th><th>31.03.2023</th></t<>	Internet State		30.09.2023	30.06.2023	30.09.2022	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2023
Reconstitution operations $1.947.99$ $2.100.27$ $1.029.14$ $4.048.26$ $2.260.21$ 7.7 Reference $1.977.90$ $2.177.40$ $1.029.48$ $2.260.231$ 7.7 Reference $1.977.69$ $2.107.40$ $1.029.48$ $2.201.33$ 7.7 Reference $1.976.95$ $1.976.95$ $3.646.60$ $1.839.10$ $6.67.60$ Reference $1.900.85$ $1.900.85$ $1.913.85$ $3.646.60$ $1.839.10$ $6.67.60.60$ Reference $1.900.85$ $1.910.85$ $3.646.60$ $1.839.10$ $6.7.60.75$ Reference $1.910.85$ $1.92.81$ $1.92.81$ $1.92.81$ $3.9.65.60$ $1.839.10$ Reference $2.13.4$ 2.091 $1.33.85.2$ $3.2.57$ $3.9.2.50$ $3.9.2.57$ $3.9.2.50$ Reference $2.17.40$ $1.33.85.61$ $1.01.63$ $3.0.26$ $3.1.7.5$ $3.0.26$ $3.7.7.6$ Reference $1.02.91$ $1.02.91$ $2.0.26$ 91.51 $2.2.60.25$	Resention 1,947-90 2,000.27 1,002-14 4,048.2.6 2,260,21 7,7 Subtrations 1,917-90 2,000.2 2,177-9 1,029-48 4,048.2.6 2,260,21 7,7 Subtrations 1,917-90 1,077-90 1,079-48 4,048.2.6 2,260,21 7,7 Subtrations 1,715-90 2,077-9 1,029-48 4,048.2.6 2,260,13 7,7 Subtrations 1,715-90 1,715-90 1,715-90 1,717-90 1,7	Income				30,09.2023	30.09.2022	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Differencies 29/0 7.22 0.24 36.22 1.12 Differencies 1.976.90 2.007.40 1.0793.48 4.084.46 2.361.33 7 Referencies 1.976.30 2.007.40 1.975.30 1.902.71 777.05 3.666.60 1.839.10 6. Dial Referencies 1.913.30 1.93.33 3.257 2.361.33 7.7 Dial Referencies 1.914 1.33.38 3.257 2.361.33 7.7 Dial Referencies 2.143 3.646.60 1.839.10 6. 6. Dial Referencies 2.13.38 3.257 2.35.30 3.256 3.0.36 Dial Referencies 2.13.34 2.05.3 3.0.36 6. 6. Dial Referencies 2.143 2.06.40 1.03.34 2.00.35 1.7 Dial Referencies 2.31.3 2.32.5 2.30.36 6. 6. Dial Referencies 2.31.30 2.35.3 2.32.5 5.3.36 6. Dial Referencies 2.30.3 <t< td=""><td>Revenue from operations</td><td>1,947.95</td><td></td><td>1.029.14</td><td>4.048.26</td><td>2 260 21</td><td>L SVVL</td></t<>	Revenue from operations	1,947.95		1.029.14	4.048.26	2 260 21	L SVVL
Indent from operations $1.97()9$ 2.10709 2.10709 2.06133 2.26133 7.7 Real (Mentini Connued 1.74339 1.9071 56735 3.64660 1.8360 6.6 Real (Mentini Connued 1.74339 1.9071 56735 3.64660 1.8360 6.6 Real (Mentini Connued 1.74390 1.9091 536560 1.8910 6.6 Real (Repress 1.9110 1.336060 1.3766060 1.37660 6.6 Repression anonization expenses 1.9110 2.336060 1.3766060 7.7 Repression anonization expenses 1.9110 2.36460 1.3766060 7.7 Repression anonization expenses 1.9110 2.36460 1.3766060 7.7 Respectsor 1.756060 1.3766060 1.7606060 7.7 Respectsor 1.760606060 1.91606060 1.7606060 1.7606060 <td>Indefinition 197.6.9 2.107.49 1.092.46 4.08.4.48 2.2.01.33 7 Det (Matter) Creamed 1.743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.1743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.1743.39 1.33.33 8.13.33 8.13.33 8.13.23 8.23.61 6 Det (Preces) 2.13.4 2.094 2.33.2 2.23.25 59.2.6 91.51 6.2.3 Det (Preces) 2.13.4 2.094 2.00.20 91.51 6.2.3 7.7 Det (Preces) 2.00.50 2.01.65 1.00.72 1.174.25 7.7 Det (Preces) State 2.02.64 91.51 62.35 50.2.6 Det (Preces) Det (Preces) 1.00.72 1.174.25 7.7 Det (Preces) Det (Preces) 0.1.65 1.66<!--</td--><td>Other income</td><td>29.00</td><td></td><td>0.34</td><td>36.22</td><td>110</td><td>1.0FF1</td></td>	Indefinition 197.6.9 2.107.49 1.092.46 4.08.4.48 2.2.01.33 7 Det (Matter) Creamed 1.743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.1743.39 1.902.71 767.05 3.646.60 1.839.10 6 Det (Matter) Creamed 1.1743.39 1.33.33 8.13.33 8.13.33 8.13.23 8.23.61 6 Det (Preces) 2.13.4 2.094 2.33.2 2.23.25 59.2.6 91.51 6.2.3 Det (Preces) 2.13.4 2.094 2.00.20 91.51 6.2.3 7.7 Det (Preces) 2.00.50 2.01.65 1.00.72 1.174.25 7.7 Det (Preces) State 2.02.64 91.51 62.35 50.2.6 Det (Preces) Det (Preces) 1.00.72 1.174.25 7.7 Det (Preces) Det (Preces) 0.1.65 1.66 </td <td>Other income</td> <td>29.00</td> <td></td> <td>0.34</td> <td>36.22</td> <td>110</td> <td>1.0FF1</td>	Other income	29.00		0.34	36.22	110	1.0FF1
Dynome Dynome <thdyno< th=""> <thdyno< th=""> <thdynom< th=""></thdynom<></thdyno<></thdyno<>	Optimum Control Control <t< td=""><td>Total income from operations</td><td>1,976,99</td><td></td><td>1,029.48</td><td>4.084.48</td><td>2.261.33</td><td>7.478.1</td></t<>	Total income from operations	1,976,99		1,029.48	4.084.48	2.261.33	7.478.1
Control 1,74.3.80 1,90.2.71 767.05 3,646.60 1,839.10 6,6 Singer Interents: 15.90 (19.08) 35.58 (3.11) 13.76 66 Singer Interents: 51.08 35.38 35.36 55.30 55.36 55.31 96.31 Single Interents: 51.08 35.38 35.37 23.30 95.31	Market for constant 1.73.39 1.902.71 767.05 3.646.60 1.839.10 6. Dense for Material Constant 31.38 1.902.71 767.05 3.646.60 1.839.10 7.7 Dense for for texpenses 31.30 3.538 1.33.8 32.57 23.30 Protection cost 19.19 3.3.8 1.3.38 32.57 23.30 Protection cost 17.3.12 96.51 10.0.52 37.3.25 90.26 Protection cost 1.3.3.8 3.3.3 2.3.3 23.3.7 23.3.0 Protection cost 1.3.3.8 2.3.3 23.3.7 23.3.0 17.4.25 90.26 Protection cost 1.3.3.8 2.0.3.6 3.9.4.3 2.0.3.6 91.51 62.3.5 Old copress 1.3.3.8 2.0.3.6 3.9.3.2.7 2.9.3.5 1.7.3.5 1.7.3.5 Old copress 1.3.3.6 3.0.3.6 3.0.3.5 3.0.3.5 1.6.3 1.7.4.5 Old copress 1.3.3.8 2.0.3.6 3.0.3.5 3.0.3.5 1.	Expenses			-			01:07:161
Diage in horeneoics 1590 (19.08) 55.98 (3.18) 13.76 33.31 33.76 33.31 33.76 33.31 33.76 33.31 33.76 33.33 33.75	Mage In Insertance 13.90 (19.08) 55.98 (3.18) 13.76 Influescends 19.01 33.83 33.63 43.86 0.4.71 29.31 Influescends 19.10 13.38 33.63 13.38 30.23 30.36 Influence costs 19.10 13.38 30.47 29.31 30.33 30.36 Influence costs 21.34 20.31 20.36 100.72 30.23 30.32 Obstending 21.34 20.31 20.05 100.82 30.23 30.35 Obstending 19.24.91 20.68.06 1.00.82 39.92.97 21.43 23.36 Obstending 20.31 20.36 20.36 91.51 62.38 7. Obstending 20.36 0.47 40.47 40.47 40.47 40.47 40.47 Obstending 20.36 15.54 80.66 47.74 7. 47.74 7. Obstending 20.36 15.54 80.56 47.74 7	Cost of Material Consumed	1,743.89		767.05	3,646.60	1.839.10	6.612 15
implove benefic expenses 51.08 53.63 45.86 104.71 98.31 infinition and montration expenses 21.34 20.91 13.38 32.57 25.330 opneant to NSE 21.34 20.91 13.38 170.02 174.25 50.66 opneant to NSE 7.3 20.91 20.92 39.92.97 21.92.49 20.91 opneant to NSE 1.924.91 2.068.06 1.00.22 3.97.92 174.25 7. Obst expenses 1.924.91 2.068.06 1.00.22 3.97.92 7.97.98 7. Obst expenses 1.924.91 2.068.06 1.00.22 3.97.92 6.2.35 7. Obst expenses 1.00.22 3.94.3 2.0.26 91.51 6.2.35 7. Obst expenses 1.2.50 0.76 0.75 1.2.50 1.6.0 1.6.23 7. Obst expenses 0.76 0.75 1.5.54 91.51 62.35 7. Obst expenses 0.76 0.55 1.65 1.65	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Change In Inventories	15.90		55.98	(3.18)	13.76	(37.8*
manual consist 19,19 13,38 33,57 23,30 13,33 33,57 23,30 1 Dependition and monitation expenses $21,34$ $20,91$ $25,32$ $42,25$ $50,26$ 1 Deferation and monitation expenses $1,32,31$ $96,51$ $10,02,22$ $39,32,97$ $21,34,92$ $7,3$ Ond express $1,92,430$ $2,34,33$ $20,26$ $91,51$ $62,35$ $7,3$ Ond express $1,92,430$ $2,34,33$ $20,26$ $91,51$ $62,35$ $7,3$ Ordifications before exceptional titems and tax $5,20$ $20,26$ $91,51$ $62,35$ $7,3$ Ordifications before tax $5,20$ $20,26$ $91,51$ $62,35$ 11 Ordifications before tax $5,20$ $0,52$ $20,26$ $91,51$ $62,35$ $7,3$ Ordifications before tax $5,20$ $0,52$ $10,62$ $1,60$ $7,74$ National rescences $0,30$ $0,52$ $1,55,41$ $80,66$ $47,74$ $1,$	functional metric constant 19,10 13,38 13,38 33,57 23,30 1 With the NSI function and mortalition explores 21,34 20,91 25,32 42,35 50,26 1 With the NSI function and mortalition explores 73,31 96,51 101,63 170,02 174,25 42,35 50,26 1 Other explore 52,03 39,43 20,02 39,93,37 21,95,98 7,3 Orifiduals before exceptional frams and tax 52,06 39,43 20,35 10,15 6,23,55 1 Confiduals before exceptional frams and tax 52,08 39,43 20,35 10,51 6,23,55 1 Confiduals before exceptional frams and tax 52,06 91,51 6,23,55 1 1 Contract as 21,06 0,35 1,069,25 39,43 1,050 1 1 Contract as 21,06 0,35 1,05 1,65 1 1 Contract as 21,05 0,35 1,55 1 1 2 <td< td=""><td>Employee benefit expenses</td><td>51.08</td><td></td><td>45.86</td><td>104.71</td><td>98.31</td><td>11921</td></td<>	Employee benefit expenses	51.08		45.86	104.71	98.31	11921
Optication and anoritation expanses 21.34 20.91 25.32 42.25 50.26 10.13 Marention submer to NSE 73.31 96.51 101.63 170.02 170.25 50.26 91.51 $a0.23$ $a0.23$ $a0.23$ Interpreted $1.924.91$ $20.68.06$ $1.009.2.2$ 39.02 91.51 $a0.23$ $a0.23$ interpreted 39.43 20.26 91.51 $a0.23$ $a0.23$ $a0.23$ interpreted 39.43 20.26 91.51 $a0.23$ $a0.23$ Defended and $a0.27$ 12.50 0.53 10.62 17.6 $a0.23$		Finance costs	19.19		13.38	32.57	23.30	47.83
with NEEcynant to NEE 73.51 96.51 101.63 170.02 174.35 a with expenses $1,924.91$ $2,068.06$ $1,00.22$ 319.297 2198.98 7.3 roll formes $1,924.91$ $2,068.06$ $1,00.22$ 319.43 20.26 31.51 $6.2.35$ 1 roll formes 52.08 39.43 20.26 91.51 $6.2.35$ 1 1 roll forme tax 52.08 39.43 20.26 91.51 $6.2.35$ 1 1 roll forme tax 12.50 0.76 0.55 11.65 $1.62.35$ 1 1 roll forme tax 12.50 0.76 0.55 11.65 1.60 1 1 roll forme tax 0.89 0.76 0.55 11.65 1.60 1 1 roll forme tax 0.89 0.76 0.55 11.65 1.60 1 1 roll forme tax 0.89 0.76 0.55 1.65 1.60 1 1 roll forme tax 0.89 0.76 0.55 1.65 1.67 1 1 roll forme tax 0.89 0.76 0.55 1.65 1.67 1 1 roll forme tax 0.89 0.76 0.55 1.65 1.67 1 1 roll for roll for tax 0.89 0.76 0.55 1.65 1.67 1 1 roll for rol	Type Type <t< td=""><td>Depreciation and amortization expenses</td><td>21.34</td><td></td><td>25.32</td><td>42.25</td><td>50.26</td><td>100.49</td></t<>	Depreciation and amortization expenses	21.34		25.32	42.25	50.26	100.49
Diff expenses 73.51 96.51 101.63 170.02 174.25 74.35 outle expenses $1.924.91$ $2.086.06$ $1.009.22$ $3.92.97$ $2.195.08$ 7.3 Serptional trens $32.04.3$ $2.02.6$ 91.51 62.35 7.3 Volt(Lass) before exceptional items and tax $5.20.8$ 39.43 $2.02.6$ 91.51 62.35 1 Volt(Lass) before tax $5.20.8$ 39.43 20.26 91.51 62.35 1 Volt(Lass) before tax $5.20.8$ 39.43 20.26 91.51 62.35 1 Volt(Acabi $1.00.5$ $1.00.5$ $1.55.6$ $1.6.21$ 62.35 1 Volt Cealit $1.25.6$ 0.75 $1.6.21$ 62.35 1.6 Nat Creating $1.60.5$ $1.55.6$ $1.55.6$ $1.6.21$ $1.6.21$ Nat Creating $1.60.5$ $1.55.6$ $1.55.6$ $1.6.21$ $1.6.21$ Nat Creatin $1.60.5$ $1.55.6$		Payment to NSE						
oil expenses 1,924,91 2,068,06 1,009,22 3,992,97 2,198,98 $7,3$ volit(lass) before exceptional items and tax 5,308 39,43 20,26 91,51 6,2,35 1 volit(lass) before tax 53,08 39,43 20,26 91,51 6,2,35 1 rolit(lass) before tax 52,08 39,43 20,26 91,51 6,2,35 1 rolit(lass) before tax 12,50 12,50 12,50 1,60 1 1 Current tax 12,50 0,65 1,55 1,56 1,60 1 1 Ubid cetta 0,89 0,75 1,55,4 80,66 47,74 1 Mat cetta 0,89 0,75 1,55,4 80,66 47,74 1 Mat cetta 1,00 15,54 80,66 47,74 1 1 Mat cetta 1,01 40,47 (162,77) 1,000,55 47,74 2 ont dot eventue for the period/ser (VII-WIII) 40,47 (122,58)	Old expresses 1.09.21 3.99.29 2.198.98 7.3 Ord expresses	Other expenses	73.51		101.63	170.02	174.25	421.81
rotif(Loss) before exceptional terms and tax 52.08 39.43 20.26 91.51 62.35 0.1 rockeptional terms 52.08 39.43 20.26 91.51 62.35 1 rockeptional terms 52.08 39.43 20.26 91.51 62.35 1 rockeptional terms 12.50 12.50 16.21 62.35 16.0 rockeptional terms 12.50 12.50 16.5 16.0 16.71 Obtened tax 12.50 0.65 1.60 62.35 16.62 Mat creatified term 0.89 0.76 0.52 16.62 16.71 Mat creatified term 0.89 0.76 0.52 16.62 17.6 Mat creatified term 0.89 0.76 0.52 16.62 47.74 1 Mat creatified to profit or loss: $0.160.55$ 15.54 80.66 47.74 1.74 Mat creatified to profit or loss: $1.752.27$ $1.600.55$ 1.77	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Total expenses	1,924.91		1,009.22	3,992.97	2,198.98	7.320.51
xceptional tense	Activities S2,08 39,43 20.26 91.51 62.35 1 reductions is express is express 5.27 12.50 (6.23) 16.01 is express is express 12.50 0.76 0.55 1.65 1.60 Current tix 12.50 0.76 0.55 1.65 1.60 Deferred ix 0.89 0.76 0.55 1.60 4774 1 Deferred ix 161 control tries 1.62.77 $1.52.27$ $1.00.55$ 1.72 2.03 Of other regulations for the period/ser (VII-VIII) 0.47 $1.752.27$ $1.000.55$ 1.774 2.4 Of other regulations for the solute share shall be $1.752.27$ $1.000.55$ $1.722.27$ 1.76 distere(Profit/(Loss) before exceptional items and tax	52.08		20.26	91.51	62.35	157.67
rotit(Loss) before fax52.08 39.43 20.26 91.51 62.35 1 in expensesin expenses 1.250 1.50 1.621 $6.2.36$ 1.621 Current tax 1.250 0.76 0.55 1.60 1.621 1.621 Current tax 0.89 0.76 0.55 1.60 1.621 1.601 Mal Credit 1.621 1.621 1.621 1.621 1.621 1.621 Mal Credit 1.612 1.612 1.621 1.621 1.601 1.621 Mal Credit 1.612 1.621 1.621 1.621 1.621 1.601 Mal Credit 1.612 1.621 1.621 1.612 1.612 1.612 Mal Credit 1.612 1.621 1.621 1.601 1.721 1.600 1.721 Otal other comprehensive income 1.72221 $1.62.77$ $1.600.55$ 1.7221 1.72	notif(use) before (ax) 52.08 39.43 20.26 91.51 62.35 01.31 ax express ax express 12.50 5.27 12.50 62.35 1.60 Deferred tax 0.89 0.76 5.27 12.50 1.60 1.60 Deferred tax 0.89 0.76 5.57 1.55 1.60 1.60 Deferred tax 0.89 0.76 5.53 1.65 1.60 1.60 Mat Creatif 0.89 0.77 40.19 15.54 80.46 47.74 1 Mat Creatifier for fray: 1 (162.77) 1 1.60 2.7 Off to relax; 1 (162.77) 1 47.74 1 2 Mat Creatifier for for tax; 1 1.72.52 1.55.4 80.46 47.74 2 Mat Creatifier for for tax; 1 1.72.52 1.55.22 1.73.23 1.7 Mat Creatifier for for tax; 1 1.75.227 1.000.55 1.7 1.7	Exceptional items						
a ceptores at express at express at express b constraints constraints <thconstraints< th=""> <thconstraints< th=""></thconstraints<></thconstraints<>	m expenses m expenses 12.50 5.27 12.50 16.21 Current last 1.0 0.89 0.76 5.27 12.50 16.21 Defend as 0.89 0.76 0.55 1.65 1.60 1.60 Defend is 0.89 0.76 0.55 1.65 1.60 1.61 Defend is 0.80 0.76 0.55 1.65 1.60 1.62 Mat Credit 40.47 10.19 15.54 80.66 4774 1 the rompreheasive income 1.155.21 11.62.77) 1.60.55 1.77 2.47 ond other comprehensive income 1.752.21 1.752.27 1.55.24 80.16 1.73 off comprehensive income 1.752.27 1.752.27 1.00.55 1.77 2.41 off comprehensive income 1.752.27 1.752.27 1.752.27 1.790.55 1.77 off comprehensive income 0.16 0.35 0.16 0.46 0.48 off comprehensive income 1.752.	Prolit/(Loss) before (ax	52.08		20.26	91.51	62.35	157.67
Outment tax 12.50 12.50 16.21 16.21 $0.Hat Credit 0.89 0.76 0.55 1.65 1.60 0.Hat Credit 0.89 0.76 0.55 1.65 1.60 0.Hat Credit 0.89 0.76 0.55 1.60 47.74 1 0.Hat Credit 0.80 0.76 47.74 80.66 47.74 1 0.16 trougnethous (net of fax) 0.40 1.60.71 1.60 47.74 1 0.16 trougnethous (net of fax) 0.47 1.62.77 1.62.77 1.60 47.74 1 0.16 trougnethous (net of fax) 0.47 1.52.51 1.52.52 1.55.4 (82.11) 47.74 2.3 0.16 trougnethous for the period/year (VII+VIII) 1.752.27 1.52.42 (82.11) 47.74 2.3 0.16 trougnethous for the period/year (VII+VIII) 1.752.27 1.000.55 1.772 1.772 1.772 0.16 trougnet (not the period/year (VII+VIII) $	Outment law 12.50 5.27 12.50 16.21 6.21 Deferred tax 0.89 0.76 0.55 1.65 1.60 1.60 Mala Cacifi ter forfulcasi) for the periodyser 0.89 0.76 0.55 1.65 1.60 Mala comprehensive income (net of tax) 40.47 40.19 15.54 80.66 47.74 1 the romprehensive income (net of tax) 1 (162.77) 1 1.60 2.7 ons that vill not be reclassified to profit or loss: 1 1.62.77 1 1.75 2 2 ont other comprehensive income 1 40.47 (122.58) 15.54 (82.11) 47.74 2 ont other expresion for the periodyser (VIF-VIII) 40.47 (122.58) 15.54 (82.11) 27.41 2 off-ond comprehensive income 1.752.27 1.752.27 1.000.55 1.772.23 2 2 off-ond comprehensive income 2.332.55 2.332.55 685.41 2 2 3 3 3	ax expenses						
Deletred tax 0.89 0.76 1.65 1.60 1.60 Mat Credit 0.55 1.65 1.60 1.60 1.60 Mat Credit 0.55 1.65 1.60 1.74 1.60 tet routerbasive income (net of tax) 0.47 40.47 $1.62.77$ 0.66 47.74 1.74 ther comprehensive income 0.61 $1.5.54$ 80.66 47.74 1.74 cons that will not be reclassified to profit or hose: $1.64.77$ $1.62.77$ $1.60.57$ 1.72 cons that will not be reclassified to profit or hose: $1.752.27$ $1.55.4$ 80.66 47.74 2.74 cons that will not be reclassified to profit or hose: $1.752.27$ $1.752.27$ $1.752.27$ 1.76 cold comprehensive income for the period/sear (VIH-VIII) $0.4.7$ $1.752.27$ $1.752.27$ $1.752.27$ 1.772 $1.772.27$ $1.772.27$ 1.774 2.74 dicate(0) $1.752.27$ $1.752.27$ $1.752.27$ 1.774 2.74 2.74 </th <td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td> <td>a) Current tax</td> <td>12.50</td> <td></td> <td>5.27</td> <td>12.50</td> <td>16.21</td> <td>54.24</td>	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	a) Current tax	12.50		5.27	12.50	16.21	54.24
Matrix 40.47 162.77 80.66 47.74 27.74 11 ems that will not be reclassified to profit or loss: 10.47 162.77 $1(62.77)$ 175 175 ems that will not be reclassified to profit or loss: 10.47 162.77 162.77 175 175 ens that will not be reclassified to profit or loss: 175.54 155.44 82.11 47.74 29 otal comprehensive income for the periodycar (VIHVIII) 40.47 (122.58) 1.554 (82.11) 47.74 29 otal comprehensive income for the periodycar (VIHVIII) $1.752.27$ $1.752.27$ $1.752.27$ $1.752.27$ $1.752.27$ 1.775 of comprehensive income for the periodycar (VIHVIII) $2.332.55$ $2.322.22$ $1.752.27$ $1.700.55$ 1.772 1.775 fict equity (sceluding revalue of the share shall he <t< th=""><td>Matrix Matrix Matrix</td><td>o) Deferred tax</td><td>0.89</td><td></td><td>0.55</td><td>1.65</td><td>1.60</td><td>0.0</td></t<>	Matrix	o) Deferred tax	0.89		0.55	1.65	1.60	0.0
Iter comprehensive income (net of tax) 40.47 40.47 40.47 40.47 40.47 40.47 40.47 40.47 40.47 40.47 40.47 40.47 $1.5.54$ 80.66 47.74 1.12 ems that will not be reclassified to profit or loss: (162.77) (17.76) (17.76) (17.76) (17.76)	ct Profit(Loss) for the period/year 40.47 40.19 15.54 80.66 47.74 112 ther comprehensive income (ret of ta.) the reclassified to profit or loss: $1(62.77)$ $ -$ </td <td>o) Mat Credit</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	o) Mat Credit						
ther comprehensive income (net of tax) </th <td>ther comprehensive income (act of tax)(162.77)(162.77)(162.77)(162.77)cms that will not be reclassified to profit or loss:(162.77)(162.77)(162.77)(162.77)otal other comprehensive incomeotal other comprehensive income(162.77)(162.77)(162.77)(162.77)otal other comprehensive income(161.77)(162.77)(162.77)(162.77)(162.77)(162.77)otal other comprehensive income(110.17)(112.58)(15.54)(182.11)(17.74)(12.98)otal comprehensive income(1752.27)1,752.271,752.271,752.271,752otal comprehensive income2,332.552,322.55(685.41)2,332.55(17.74)2,414fibrate()(15.10)(16.10)(16.10)(16.10)(17.74)(17.75)fibrate()(17.810)(17.810)(17.82)(17.810)(17.74)(17.75)fibrate()(17.91)(17.91)(17.91)(17.91)(17.75)(17.91)fibrate()(18.10)(18.10)(19.11)(11.75)(11.75)(11.75)Basic(18.10)(19.11)(11.75)(11.75)(11.75)(11.75)(11.75)Diluted(12.11)(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)<</td> <td>Vct Profit/(Loss) for the period/year</td> <td>40.47</td> <td>40.19</td> <td>15.54</td> <td>80.66</td> <td>47.74</td> <td>112.45</td>	ther comprehensive income (act of tax)(162.77)(162.77)(162.77)(162.77)cms that will not be reclassified to profit or loss:(162.77)(162.77)(162.77)(162.77)otal other comprehensive incomeotal other comprehensive income(162.77)(162.77)(162.77)(162.77)otal other comprehensive income(161.77)(162.77)(162.77)(162.77)(162.77)(162.77)otal other comprehensive income(110.17)(112.58)(15.54)(182.11)(17.74)(12.98)otal comprehensive income(1752.27)1,752.271,752.271,752.271,752otal comprehensive income2,332.552,322.55(685.41)2,332.55(17.74)2,414fibrate()(15.10)(16.10)(16.10)(16.10)(17.74)(17.75)fibrate()(17.810)(17.810)(17.82)(17.810)(17.74)(17.75)fibrate()(17.91)(17.91)(17.91)(17.91)(17.75)(17.91)fibrate()(18.10)(18.10)(19.11)(11.75)(11.75)(11.75)Basic(18.10)(19.11)(11.75)(11.75)(11.75)(11.75)(11.75)Diluted(12.11)(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)(11.11)fibrate()(11.11)(11.11)(11.11)(11.11)<	Vct Profit/(Loss) for the period/year	40.47	40.19	15.54	80.66	47.74	112.45
emit that will not be reclassified to profit or loss: (162.77) (175.27) (162.77) (175.27) (160.55) (17.52.27)	cons that will not be reclassified to profit or lass:(162.77)(162.77).(162.77).oral other comprehensive incomeand other comprehensive income (162.71) (162.77) (162.77) (162.77) (162.77) oral other comprehensive incomeand other comprehensive income (102.58) 15.54 (82.11) 47.74 298 oral comprehensive income for the period/year (VII+VIII) (122.58) 15.54 (82.11) 47.74 298 oral comprehensive income $1,752.27$ $1,752.27$ $1,752.27$ $1,762$ $1,752$ dirated unity share capital (face value of the share shall be dirated) $2,332.55$ $2,332.55$ 685.41 $2,332.55$ 685.41 $2,341.69$ Sin Rs. (Face Value of Rs. 10- each)* 0.23 0.23 0.16 0.46 0.48 0.16 Diluted 0.23 0.23 0.23 0.16 0.46 0.48 0.16 Diluted 0.23 0.23 0.16 0.46 0.48 1^-1	Other comprehensive income (net of tax)				Ĩ		
of al other comprehensive income 47.74 47.74 298 of al comprehensive income for the period/year (VII+VIII) 40.47 (122.58) 15.54 (82.11) 47.74 298 aid-up equity share capital (face value of the share shall bc $1,752.27$ <td>oth other comprehensive income oth other comprehensive income 47.74 47.74 298 of al comprehensive income for the period/year (VII+VII) 40.47 (122.58) 15.54 (82.11) 47.74 298 of al comprehensive income for the period/year (VII+VII) $1,752.27$ <t< td=""><td>tems that will not be reclassified to profit or loss:</td><td></td><td>(162.77)</td><td></td><td>(162.77)</td><td></td><td>186</td></t<></td>	oth other comprehensive income oth other comprehensive income 47.74 47.74 298 of al comprehensive income for the period/year (VII+VII) 40.47 (122.58) 15.54 (82.11) 47.74 298 of al comprehensive income for the period/year (VII+VII) $1,752.27$ <t< td=""><td>tems that will not be reclassified to profit or loss:</td><td></td><td>(162.77)</td><td></td><td>(162.77)</td><td></td><td>186</td></t<>	tems that will not be reclassified to profit or loss:		(162.77)		(162.77)		186
otal comprehensive income for the period/year (VII+VIII) 40.47 (122.58) 15.54 (82.11) 47.74 29 aid-up equity share capital (face value of the share shall be $1,752.27$ $1,752.27$ $1,000.55$ $1,752.27$ $1,000.55$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,000.55$ $1,752.27$ $1,752.27$ $1,752.27$ $1,000.55$ $1,752.27$ $1,752.27$ $1,752.27$ $1,000.55$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,752.27$ $1,772.22$	otal comprehensive income for the period/year (VIH-VII) 40.47 (122.58) 15.54 (82.11) 47.74 22 aid-up equity share capital (face value of the share shall be $1,752.27$ $1,000.55$ $1,752.27$ $1,000.55$ $1,75$ $2,41$ direate() $1,752.27$ $1,752.27$ $1,000.55$ $1,75$ $1,75$ there equity (excluding revaluation reserve) $2,332.55$ $2,292.02$ 685.41 $2,332.55$ 685.41 <td>otal other comprehensive income</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	otal other comprehensive income						
ald-up equity share capital (face value of the share shall be 1,752.27 1,000.55 1,752.27 1,000.55 1,752.27 1,000.55 1,752.27 1,000.55 1,752.27 1,775 <th< th=""><td>aid-up equity share capital (face value of the share shall be 1,752.27</td><td>"otal comprehensive income for the period/year (VII+</td><td></td><td>(122.58)</td><td>15.54</td><td></td><td></td><td>100 67</td></th<>	aid-up equity share capital (face value of the share shall be 1,752.27	"otal comprehensive income for the period/year (VII+		(122.58)	15.54			100 67
there equity (excluding revaluation reserve) 2,332.55 2,292.02 685.41 2,332.55 685.41 2,332.55 PS in Rs. (Face Value of Rs.10/- each)* • • 0.23 0.23 0.23 0.16 0.46 0.48 Diluted • • 0.23 0.23 0.16 0.46 0.48	there equity (excluding revaluation reserve) 2,332.55 2,292.02 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,332.55 685.41 2,341 PS in Rs. (Face Value of Rs.10 st each)* • 0.23 0.23 0.16 0.46 0.48 0.48 Diluted • <t< td=""><td>aid-up equity share capital (face value of the share sl idicated)</td><td></td><td>1.752.27</td><td>1 000 55</td><td>(c)</td><td>1 000 22</td><td>20:074</td></t<>	aid-up equity share capital (face value of the share sl idicated)		1.752.27	1 000 55	(c)	1 000 22	20:074
PS in Rs. (Face Value of Rs.10/- each)* 0.23 0.23 0.23 0.16 0.46 0.48 Basic 0.23 0.23 0.16 0.46 0.48 Diluted 0.23 0.23 0.16 0.46 0.48	PS in Rs. (Face Value of Rs. 10'- each)* PS in Rs. (Face Value of Rs. 10'- each)* PS in Rs. (Face Value of Rs. 10'- each)* PS in Rs. (Face Value of Rs. 10'- each)* PS in PS i	Other equity (excluding revaluation reserve)	2.332.55	2.292.02	185.41	3 337 55	1,000,1	17.751.1
Basic · 0.23 0.23 0.16· 0.46 0.48 Diluted 0.23 0.23 0.16 0.46 0.48	Basic . 0.23 0.16 0.46 0.48 Diluted 0.23 0.23 0.16 0.48 0.48 0.46 0.48 0.48 0.48 0.46 0.48 0.48 0.48 0.48 0.48 0.48 0.48 0.48	(PS in Rs. (Face Value of Rs.10/- each)*			I		T+*CDD	4,414.00
Diluted 0.23 0.23 0.16 0.48 0.48	Diluted 0.23 0.25 0.16 0.48 0.48 0.48	-Basic		0.23	• 0.16-	0.46	0.48	1.04
	ALL	-Diluted	0.23	0.23	0.16	0.46	0.48	1.04
				1820		2	01:0	1,74

•


1. The above results are as per Regulation 33 of the SEBI 09.11.2023 after being reviewed by the Audit Committee.	1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 39.11.2023 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance w	with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
 Due to re-grouping of schedules, and as per applicabilit This statement has been prepared in accordance with the Conveognised accounting practices and policies to the extent applic 	• Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier. • This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other ecognised accounting practices and policies to the extent applicable.
¹ ace : Mohali Date : 09/11/2023	For Ajooni Biotech Limited Jasjot Singh Managing Director



Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone : 0172-5020758-69 Website : www.ajoonibiotech.com E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

Statement of Assets and Liabilities For the Year ended on 30th September 2023

	DADELOVY ADO		(in Rs lakhs.)
	PARTICULARS	30TH SEP 2023	31ST MARCH 2023
[. A	SSETS		
(1)	Non - Current Assets		
	a) Property, Plant and Equipment	607.80	628.91
	b) Capital Work In Progress	75.27	26.19
	c) Investment Property		63 6
	d) Goodwill	1.4 <u>9</u> 1	
	e) Other Intangible Assets		0
	f) Intangible Assets Under Development		
	g) Biological Assets other than Bearer Plants		
	h) Financial Assets		
	(1) Investments	109.38	373.72
	(2) Trade Receivables		18 4
	(3) Loans	-	-
	(4) Other Financial Assets	800.00	1,200.00
	i) Deffered Tax Asset (net)	28.85	27.20
	j) Other Non Current Asset	230.00	150.00
2)	Current Assets		100.00
	a) Inventories	1,022.60	699.40
	b) Financial Assets		077.10
	(1) Investments		
	(2) Trade Receivables	2,179.62	2,055.11
	(3) Cash & Cash Equivalent	27.72	30.93
	(4) Bank Balances other than (iii) above		
	(5) Loans	646.82	403.35
	(6) Other Financial Asset	18.41	18.41
	c) Current Tax Assets (net)		
	d) Other Current Asset	49.57	259.93
	TOTAL	5,796.04	5,873.14



1)	Equity			
	a)Equity Share Capital		1,752.27	1,752.27
	b) Other Equity		2,319.96	2,414.66
(2)	Non-Current Liabilities			
	a) Financial Liabilities			
	(1) Borrowings		156.92	174.66
	(2) Trade Payables			1.
	(3) Other Financial Liabilties			
	b) Employee Benefit Obligations		10.61	10.61
	c) Deferred Tax Liability (net)			
	d) Other Non Current Liability			-
<u>(3)</u>	Current Liabilities			
	a) Financial Liabilities			
	(1) Borrowings		632.17	343.04
	(2) Trade Payables		865.54	1,011.11
	(3) Other Financial Liabilities			
	b) Employee Benefit Obligations		2.40	2.40
	c) Other Current Liabilities		43.67	110.16
	d) Current tax liabilities (Net)		12.50	54.24
		TOTAL –	5,796.04	5,873.14

Date: 09.11.2023 Place: Mohali For Ajooni Biotech Limited

-T-195 APAAL Jasjot Singh Managing Director DIN: 01937631



Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone : 0172-5020758-69 Website : www.ajoonibiotech.com E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

٦

'A" (1)	LOW STATEMENT FOR THE HALF YEAR ENDED 30 CASH FLOW FROM OPERATING ACTIVITIES			
	Profit/(Loss) Before Tax			91.5
	Adjustments for:			91.5
	Depreciation & Amortization	46.97		
	Change In Reserves	8.99		
	Interest & Finance Charges	32.57		
	Interest Income	-27.77	60.76	
	Operating Profit before Working Capital Changes			152.2
	Adjustments for:			
	Decrease/(Increase) in Receivables	-124.51		
	Decrease/(Increase) in Inventories	-323.20		
	Decrease/(Increase) in Loans and Other Advances	-243.47		
	Decrease/(Increase) in Other Current Assets	208.71		
	Increase/(Decrease) in Trade Payables	-145.57		
	Increase/(Decrease) in Other Current Liabilities	-66.49	-694.53	
	Cash generated from operations			(542.20
	Tax paid prev year		-54.31	(* 1414)
	Net Cash flow from Operating activities	Ē		(596.5)
(2) CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Tangible Assets/ Intangible		1	
	Assets/ Capital Work-In-Progress		-76.02	•
	claim received against Fixed Asset		3.44	
	Advance For Land		-80	
	Investment in fdr's redeemed		400	
	(Increase)/Decreaseby sale/purchase in Non-Current In	nvestmen	101.56	
	Interest Income		27.77	
	Net Cash used in Investing activities			376.7
(3) CASH FLOW FROM FINANCING ACTIVITIES			
	Proceeds from/ (Repayment) of Long term Borrowings		-17.74	
	Increase/(Decrease) in Short Term Borrowings		289.13	
	Interest and Other Finance Costs paid		(32.57)	
	Net Cash used in financing activities			238.8
."	Net increase in cash & Cash Equivalents			19.00
	Add: Cash and Cash equivalents at the			
	Beginning of the Year 1.04.2023			30.9
•	Cash & Cash Equivalents at 30.09.2023			27.72

*



Harjeet Parvesh & Company CHARTERED ACCOUNTANTS (A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th SEPTEMBER 2023("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

